FDG and Non-FDG Radiopharmaceuticals for PET Imaging in Invasive Lobular Breast Carcinoma

Invasive lobular cancer (ILC) is the second most frequent histological type of breast cancer (BC) and includes a heterogeneous spectrum of diseases with unique characteristics, especially the infiltrative growth pattern and metastatic spread. [<sup>18</sup>F]fluoro-2-deoxy-D-glucose posi...

Full description

Bibliographic Details
Main Authors: Laura Gilardi, Lighea Simona Airò Farulla, Giuseppe Curigliano, Giovanni Corso, Maria Cristina Leonardi, Francesco Ceci
Format: Article
Language:English
Published: MDPI AG 2023-05-01
Series:Biomedicines
Subjects:
Online Access:https://www.mdpi.com/2227-9059/11/5/1350
Description
Summary:Invasive lobular cancer (ILC) is the second most frequent histological type of breast cancer (BC) and includes a heterogeneous spectrum of diseases with unique characteristics, especially the infiltrative growth pattern and metastatic spread. [<sup>18</sup>F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (FDG-PET/CT) is extensively used in oncology and BC patient evaluation. Its role in ILCs is considered suboptimal due to its low FDG avidity. Therefore, ILCs could benefit from molecular imaging with non-FDG tracers that target other specific pathways, contributing to precision medicine. This narrative review aims to summarize the current literature on the use of FDG-PET/CT in ILC and to discuss future opportunities given by the development of innovative non-FDG radiotracers.
ISSN:2227-9059